Genexine names new co-CEO at shareholder meeting

Neil Warma, the new co-CEO of Genexine [GENEXINE]

Genexine named Neil Warma as the new co-CEO of the company.

The decision was made during the company’s shareholder meeting held Tuesday afternoon.

Having previously served as the CEO of Nasdaq-listed Opexa Therapeutics and Viron Therapeutics, Neil Warma has more than 25 years of experience in the global biopharmaceutical industry, Genexine said. Warma has been working as Genexine’s outsider director since March last year.

Warma will work with Woo Jung-won, the current CEO.

The Seongnam-based company also said Chairman Sung Young-chul, also the founder of the company, will step down from his position. Instead, he will concentrate on drug research and development.

With Sung’s resignation, Kim Young-jin, CEO of Handok Pharmaceuticals, will take his place.

“Under founder Sung’s leadership, Genexine has grown as an innovative biopharmaceutical company with distinctive technology,” Warma said. “We will expand our business to the U.S. and European markets and offer people new drugs at reasonable prices that can save many patients across the world.”